Platinum-based chemotherapy for variant castrate-resistant prostate cancer

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3621-3630

  Aparicio, Ana M ^a   Harzstark, Andrea L ^b   Corn, Paul G ^a   Wen, Sijin ^a,c   Araujo, John C ^a   Tu, Shi Ming ^a   Pagliaro, Lance C ^a   Kim, Jeri ^a   Millikan, Randall E ^a   Ryan, Charles ^b   Tannir, Nizar M ^a   Zurita, Amado J ^a   Mathew, Paul ^a,d   Arap, Wadih ^a   Troncoso, Patricia ^a   Thall, Peter F ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE; ARGIPRESSIN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; CISPLATIN; CORTICOTROPIN; DOCETAXEL; ETOPOSIDE; GASTRIN RELEASING PEPTIDE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN; VASOPRESSIN; ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; SENSORY NEUROPATHY; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; MIDDLE AGED; MORTALITY; ORCHIECTOMY; PROSTATIC NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PLATINUM; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84879853237     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3791     Document Type: Article

References (42)

1. Mahadevia PS, Ramaswamy A, Greenwald ES, Wollner DI, Markham D. Hypercalcemia in prostatic carcinoma. Report of eight cases. Arch Intern Med 1983;143:1339-42. (Pubitemid 13067911)
2. Hindson DA, Knight LL, Ocker JM. Small-cell carcinoma of prostate. Transient complete remission with chemotherapy. Urology 1985;26:182-4. (Pubitemid 17067757)
3. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. Aclinicopathologic study of 20 cases. Cancer 1987;59:1803-9.
4. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992;147:804-7.
5. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992;147:935-7.
6. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-80. (Pubitemid 34791096)
7. Moore SR, Reinberg Y, ZhangG. Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 1992;39:411-6.
8. Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch Pathol Lab Med 1988;112:1100-5. (Pubitemid 18266523)
9. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O, et al. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001;8:431-6. (Pubitemid 34225095)
10. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16. (Pubitemid 39665537)
11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
12. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. (Pubitemid 39315318)
13. Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 1994;30A:1058-60.
14. Hesketh PJ, Crowley JJ, Burris HA III, Williamson SK, Balcerzak SP, Peereboom D, et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am 1999;5:237-41. (Pubitemid 29528752)
15. Rossi A, Martelli O, Di Maio M. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev 2013;39:498-506.
16. Canobbio L, Guarneri D, Miglietta L, Decensi A, Oneto F, Boccardo F. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993;29A:2094-6. (Pubitemid 23348122)
17. Graham TR, Yacoub R, Taliaferro-Smith L, OsunkoyaAO, Odero-Marah VA, Liu T, et al. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res Treat 2010;123:139-47.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific AntigenWorking Group. J Clin Oncol 1999;17:3461-7. (Pubitemid 29517916)
20. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
21. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
22. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008;112:521-6. (Pubitemid 351186193)
23. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009;20:703-8.
24. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001;12 (Suppl 2):S135-40.
25. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 2005;66:386-91. (Pubitemid 41138103)
26. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109-17. (Pubitemid 40477092)
27. Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844-8. (Pubitemid 47224949)
28. Steineck G, Reuter V, Kelly WK, Frank R, Schwartz L, Scher HI. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 2002;41:668-74. (Pubitemid 36106212)
29. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22:2476-81.
30. Schacht MJ, Garnett JE, Grayhack JT. Biochemical markers in prostatic cancer. Urol Clin North Am 1984;11:253-67. (Pubitemid 14123125)
31. Feuer JA, Lush RM, Venzon D, Duray P, Tompkins A, Sartor O, et al. Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer. J Investig Med 1998;46:66-72. (Pubitemid 128452771)
32. Kane RD, Mickey DD, Paulson DF. Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy. Urology 1976;8:559-62.
33. Ihde DC, Bunn PA, Cohen MH, Dunnick NR, Eddy JL, Minna JD. Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression. Cancer 1980;45:1300-10. (Pubitemid 10134863)
34. Aus G, Hugosson J, Norlen L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 1995;154:466-9.
35. Wiegand LR, Hernandez M, Pisters LL, Spiess PE. Surgical management of lymph-node-positive prostate cancer: improves symptomatic control. BJU Int 2011;107:1238-42.
36. Qin XJ, Ma CG, Ye DW, Yao XD, Zhang SL, Dai B, et al. Tumor cytoreduction results in better response to androgen ablation-a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol 2012;30:145-9.
37. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8.
38. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:2104-11.
39. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9. (Pubitemid 33126820)
40. Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743-9. (Pubitemid 46630571)
41. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, et al. Neuroendocrine prostate cancer xenografts with large-cell and smallcell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 2011;71:846-56.
42. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012;18:666-77.